Role of molecular genetics in the clinical management of cholangiocarcinoma

The incidence of cholangiocarcinoma (CCA) has steadily increased during the past 20 years, and mortality is increasing. The majority of patients with CCA have advanced or metastatic disease at diagnosis, and treatment options for unresectable disease are limited, resulting in poor prognosis. However, recent identification of targetable genomic alterations has expanded treatment options for eligible patients. Given the importance of early and accurate diagnosis in optimizing patient …
Continua a leggere

Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance

Treatment of intrahepatic cholangiocarcinoma (iCCA) is currently at a significant turning point due to the identification of isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor (FGFR) fusions that can be targeted with currently available therapies. Clinical trials of these targeted therapies have been promising, and the iCCA patients who may benefit from these targeted treatments can be identified by pathological examination prior to molecular investigations …
Continua a leggere

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years. The TOPAZ-1 trial evaluated durvalumab plus chemotherapy for patients with advanced biliary tract cancer. In this double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with previously untreated unresectable or metastatic biliary tract cancer or with recurrent …
Continua a leggere

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3. This study evaluated the safety and antitumour activity of pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with and without FGFR2 fusions or rearrangements …
Continua a leggere

Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response

Oncogenic fibroblast growth factor receptor (FGFR) gene alterations have been described in patients with cholangiocarcinoma (CCA). This post hoc analysis assessed progression-free survival (PFS) in patients who had received first- or second-line systemic therapy for advanced/metastatic CCA before enrollment in the phase II FIGHT-202 study (ClinicalTrials.gov identifier: NCT02924376) …
Continua a leggere

O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202

Cholangiocarcinoma (CCA) tumors have high genomic heterogeneity, with 40%–50% of patients with CCA harboring at least 1 clinically actionable genetic alteration. Fusions or rearrangements in the FGFR2 gene are present in 10%–15% of patients with intrahepatic CCA. Pemigatinib is an oral, potent, selective fibroblast growth factor receptor (FGFR)1, 2, and 3 inhibitor for the treatment of adults with previously treated, unresectable locally advanced/metastatic CCA with an FGFR2 fusion or other rearrangement …
Continua a leggere

Per maggiori approfondimenti visita il sito: colangiocarcinoma.net

XXIV Congresso Nazionale AIOM
Oncologia e complessità Le nuove sfide per gli oncologi
Roma, 1 – 3 ottobre 2022

Management delle tossicità emergenti da farmaci innovativi (SMART)
FAD, 22 settembre, 20 ottobre 2022

La multidisciplinarietà per il paziente oncologico: l’importanza del confronto nell’approccio pratico
FAD, 1° maggio – 31 dicembre 2022

Comunicare il Cancro, la Medicina e la Salute
FAD, giugno – dicembre 2022

L’adroterapia e l’importanza della multidisciplinarietà per una terapia personalizzata
FAD, 1° luglio 2022 – 31 dicembre 2022

Best of WCLC 2022
FAD, 1° maggio – 31 dicembre 2022

Il genere nei percorsi oncologici: #nonsoloormoni
I mercoledì dell’oncologia
Webinar ECM, 7 settembre 2022

La vaccinazione anti Herpes Zoster: le nuove raccomandazioni AIOM
Webinar, 8 settembre 2022

International Summer School on immuno-oncology
Pallanza (VB), 14 – 17 settembre 2022

La vaccinazione anti Herpes Zoster: le nuove raccomandazioni AIOM
Webinar, 15 settembre 2022